The Rare Aftereffect Nobody Warns You About
For the overwhelming majority of people, a psychedelic experience ends when the drug clears the system — hours later, with nothing but memory and (maybe) insight remaining. For a small minority, some of the perceptual changes persist: visual snow across the field of view, halos and starbursts around lights, trails behind moving objects, afterimages that linger, walls that subtly breathe when you stare at them, colors that seem more vivid than they used to. This cluster of symptoms has a name — hallucinogen persisting perception disorder, HPPD — and while it's rare, frequently distressing, and still poorly understood, anyone who uses psychedelics should know it exists, what raises the risk, and what to do if it happens.
What HPPD Actually Is — and Isn't
HPPD is classified in the DSM-5 as a disorder of persistent visual disturbances following hallucinogen use, in which the person knows the perceptions aren't real (it's not psychosis), isn't under the influence (it persists between uses), and experiences genuine distress or functional impairment as a result. Two presentations are recognized. Type I is the more benign form: brief, intermittent visual flashbacks — a sudden re-experiencing of visual phenomena days or weeks after a trip, often triggered by stress, fatigue, or entering similar settings. Most resolve. Type II is the chronic form: continuous or near-continuous visual snow and accompanying distortions that persist for months to years, waxing and waning with stress, substance use, and sleep.
The visual snow at HPPD's core is distinctive: a constant, television-static overlay across the entire visual field, present in light and dark, that the person can never quite stop noticing. Around it cluster the associated phenomena — palinopsia (afterimages and trailing), photophobia, nyctalopia (impaired night vision), floaters that command attention, and the sense that visual input arrives slightly "processed" or unreal.
What It Isn't
The popular imagination files everything weird after psychedelics under "flashbacks," but precision matters. HPPD is not:
- Psychosis. Reality testing stays intact; the person knows the snow isn't really there. (Though HPPD can coexist with, and be worsened by, anxiety.)
- PTSD. Though traumatic trips can produce flashback phenomena proper, the continuous visual-static presentation is a distinct neurological picture.
- "The drug is still in your body." LSD clears within days. HPPD is a lasting change in perceptual processing, not a lingering chemical — which is precisely what makes it interesting to neuroscientists and concerning to patients.
Who Gets It, and Why
The honest answer: nobody fully knows. HPPD appears genuinely rare — no rigorous prevalence study exists, but clinical lore and survey data suggest well under 1% of psychedelic users develop the chronic form. The risk factors that recur across case series are instructive: very frequent use (weekly or more, which blurs into the psychological-habituation territory covered elsewhere in this series), high doses, use during adolescence, pre-existing anxiety or visual sensitivity, and a propensity to hyper-attend to bodily and perceptual sensations. The last factor — a cognitive style of noticing and catastrophizing normal perceptual noise — appears central to why the snow becomes disorder rather than quirk. Everyone has some visual noise; HPPD patients can no longer filter it out, and the anxiety about it amplifies its salience in a vicious loop.
There's also a chicken-and-egg question researchers openly debate: does frequent psychedelic use cause HPPD, or do people with certain perceptual-cognitive profiles both gravitate toward heavy use and develop HPPD? The truth is likely some of both, and it matters practically: if the vulnerability is partly pre-existing, "any use is safe for everyone" is as false as "any use causes HPPD."
What To Do If It Happens
Stop all serotonergic substances immediately. Continued use is the single clearest aggravating factor in every case series. Cannabis — which intensifies perceptual phenomena in most users — should also be suspended; many patients report the snow markedly improves after quitting both.
Get evaluated, and be specific. HPPD is unfamiliar to many general practitioners. Ask for referral to a neuro-ophthalmologist (to rule out organic causes like retinal or neurological disease) and a psychiatrist familiar with the condition. A careful workup matters both for treatment and for peace of mind.
Treat the anxiety loop, which is treatable. Whatever the neurological substrate, the distress of HPPD runs substantially through attention and catastrophizing — and those respond to treatment. Patients report the most relief from the same toolkit used for health anxiety and OCD-spectrum conditions: CBT with attention-retraining components, mindfulness practice aimed at allowing the snow to exist without scanning for it, and, in some cases, medication. Case literature has explored lamotrigine, clonidine, and certain benzodiazepines with mixed, anecdotal results; nothing has robust trial support, and no one should start medication for HPPD without a specialist's guidance.
Protect the fundamentals. Sleep deprivation, stress, caffeine, and stimulants reliably worsen symptoms in patient reports. Boring advice, real effect.
Give it time. Even the chronic form tends to soften with sustained abstinence — months to years of gradual fading is the common trajectory. Many people reach a state where the phenomena persist but no longer register as distressing, which clinically is recovery.
The Prevention Question
Since HPPD can't be predicted with certainty, prevention reduces to the same risk-bending principles that recur throughout this series: don't use heavily or frequently — the distance between sessions is where the perceptual system recalibrates; avoid use in adolescence; don't push dose; and take any early warning signs (visual changes persisting after a trip, a flashback that unsettles you) as a signal to stop entirely and reassess. For the vast majority of users, HPPD will never be an issue. For the unlucky minority, early recognition and immediate abstinence make a real difference in trajectory — which is exactly why the condition deserves to be known about before, not after, the first dose.
